ArticleEuropean radiology2026
Yttrium-90 glass microsphere radioembolization as frontline treatment for hepatocellular carcinoma with localized portal vein invasion.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transarterial radioembolisation combined with targeted therapy and immune checkpoint inhibitors in advanced hepatocellular carcinoma with portal vein tumour thrombus: efficacy, safety, and dosimetric analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- Unmasking infiltrative hepatocellular carcinoma: a pictorial essay.Abdominal radiology (New York) · 2026Review
- Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients.EClinicalMedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo evaluate the outcomes of yttrium-90 radioembolization (glass microspheres) in patients with unilobar hepatocellular carcinoma (HCC) and portal vein invasion (PVI) who have preserved liver function. MATERIALS AND
methodsThis study included 48 patients with unilobar HCC and PVI, all with Child-Pugh A, treated with radioembolization at a single institution between January 2016 and December 2023. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and localized mRECIST. Overall survival (OS) and prognostic factors were evaluated using time-to-event analyses. The mean tumor absorbed dose (TAD) threshold for achieving complete response (CR) by localized mRECIST was determined using receiver operating characteristic analysis, while the threshold associated with significantly longer OS was identified using the minimum p-value approach.
resultsObjective response rates were 83% (40/48) by mRECIST and 88% (42/48) by localized mRECIST. The median OS was 47.2 months (95% CI, 19.1-52.1 months). The TAD was the only significant predictor of OS (p = 0.032, hazard ratio = 0.862 per 100 Gy, 95% CI = 0.753-0.988). A mean TAD > 574 Gy provided 50% sensitivity and 86% specificity for predicting CR by localized mRECIST, while a threshold of 586 Gy was proposed to significantly extend OS (median OS, 49.5 months for > 586 Gy and 21.9 months for ≤ 586 Gy; p = 0.021).
conclusionRadioembolization is effective for HCC with localized PVI in patients with preserved liver function, and a mean TAD > 600 Gy is proposed to achieve improved oncologic outcomes. KEY POINTS: Question What is the optimal radioembolization approach and its outcome for hepatocellular carcinoma with localized portal vein invasion (Vp1-3) in patients with preserved liver function? Findings A tumor absorbed dose exceeding 600 Gy via a tandem approach achieved complete response rates above 80% and median overall survival longer than 49.5 months. Clinical relevance Ablative radioembolization, delivering a tumor absorbed dose exceeding 600 Gy via a tandem approach, should be considered for hepatocellular carcinoma with localized portal vein tumor thrombosis (Vp1-3) in patients with preserved liver function and no extrahepatic spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.